BiotechTube
Stemina Biomarker Discovery

Stemina Biomarker Discovery

Madison, United States· Est.
stemina.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.4M

Overview

Stemina Biomarker Discovery, founded in 2007 and based in Madison, Wisconsin, is a pioneer in human cell-based toxicology testing. The company's core technology is a metabolomics platform applied to human pluripotent stem cell-derived models, which powers its flagship assays for developmental toxicity (devTOX quickPredict) and cardiotoxicity (Cardio quickPredict). These assays provide faster, cheaper, and human-relevant safety data for pharmaceutical, chemical, and consumer product companies, positioning Stemina at the forefront of the New Approach Methodologies (NAMs) movement. The company also has a diagnostic arm, NeuroPointDX, focused on developing metabolomic tests for autism spectrum disorder.

ToxicologyNeurology

Technology Platform

Proprietary metabolomics platform applied to human pluripotent stem cell (hPSC)-derived models (e.g., cardiomyocytes, developing tissues) to identify biomarker signatures predictive of toxicity and disease.

Funding History

3
Total raised:$1.4M
Grant$244K
Grant$150K
Seed$1M

Opportunities

Strong regulatory and legislative push for animal testing alternatives (NAM) creates a large, growing market for human-relevant toxicology assays.
The high cost of late-stage drug failure due to toxicity drives pharmaceutical demand for predictive early-stage screening tools.
The unmet need for objective, biological diagnostics in autism spectrum disorder presents a significant commercial opportunity for the NeuroPointDX test.

Risk Factors

Pace of regulatory and industry adoption of in vitro assays as full replacements for animal studies may be slower than anticipated.
The company requires sustained funding for operations and costly diagnostic R&D/validation, posing a challenge as a private entity.
Competition exists from other toxicology service providers and potential entrants into metabolomics-based neurological diagnostics.

Competitive Landscape

In toxicology, Stemina competes with CROs offering early discovery services (e.g., Charles River, Eurofins) and niche players specializing in stem cell-based assays. Its metabolomics focus is a key differentiator. In autism diagnostics, it faces potential competition from large diagnostic firms and other biotechs exploring genomic, proteomic, or metabolomic biomarkers, though the market for an approved test is still emerging.

More companies in Diagnostics & Precision Medicine →More companies in United States →